types

',''); } } ?>

– Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months

– These data indicate the potential for sustained improvement in quality-of-life measures for patients with symptomatic SMA and offer further evidence of possible durable effects of apitegromab

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new quality-of-life (QoL) data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment which indicate stabilization or continued improvement with apitegromab for nonambulatory patients with Types 2 and 3 spinal muscular atrophy (SMA) receiving an SMN-targeted therapy. The data were featured in a podium presentation today by Basil Darras, M.D., Associate Neurologist-in-Chief, Boston Children’s Hospital and Professor of Neurology, Harvard Medical School, at the 3rd International Scientific Congress on SMA in Barcelona, Spain (SMA Europe 2022).

“SMA can have a significant impact on the ability to perform daily activities but there is limited research on potential interventions to improve quality-of-life measures, such as increasing muscle endurance and reducing fatigue.1,2 These positive TOPAZ data indicate sustained improvements of quality-of-life measures over 24 months in the patient population studied,” said Jay Backstrom, M.D., M.P.H., Chief Executive Officer of Scholar Rock. “As the Phase 3 SAPPHIRE trial advances, these additional TOPAZ trial analyses coupled with the previously reported measures of motor function, such as HFMSE and RULM, continue to yield positive, consistent results, building the case for apitegromab as a promising new treatment option for patients with SMA.”

The TOPAZ trial assessed activities of daily living (ADL), fatigue, and muscle endurance by three tertiary endpoint measures:

  1. The Pediatric Evaluation of Disability Inventory-Computer Adaptive Test (PEDI-CAT) measures pediatric abilities through three functional domains, daily activities, mobility, and social cognition;3
  2. Patient Reported Outcome Measurement Information System (PROMIS) measures mild subjective feelings of tiredness to debilitating and sustained feelings of exhaustion, with lower scores reflecting less fatigue;4,5 and
  3. Endurance Shuttle Box and Block Test (ESBBT), a muscle endurance measurement tool, evaluates how fast a patient fatigues with the added measure of endurance6 and may be complementary to outcome measures that focus on arm motor function, such as the Revised Upper Limb Module (RULM) assessment.

The tertiary endpoint data from these measures show trends of continuous improvement over 24 months. These data are relevant for informing the therapeutic hypotheses being evaluated in the Phase 3 SAPPHIRE trial. Limitations of these exploratory quality-of-life data analyses include small patient sample sizes in an open-label study, and further exploration is warranted. Specifically, the data found:

  • Nonambulatory Type 2 patients (aged two or older who began receiving nusinersen maintenance therapy before age five) reported stabilization or continuous improvements in ADL up to a mean change from baseline of 3 points (n=14) in PEDI-CAT scores and fatigue up to a mean change from baseline of 5 points (n=10) in PROMIS scores over 24 months of apitegromab.
  • Nonambulatory Types 2 and 3 patients (aged five to 21 who began receiving nusinersen maintenance therapy at or after age five) reported stabilization or increases in ADL up to a mean change from baseline of 0.7 points (n=8) in PEDI-CAT scores, and less fatigue up to a mean change from baseline of 3.5 points (n=2) in PROMIS scores over 24 months of apitegromab. Additionally, these patients also experienced trends in improvements in fatigability and endurance measures based on mean change in ESBBT activities. The trends of improvement with ESBBT are consistent with the previously reported increases in RULM scores observed in the TOPAZ trial at 24 months.

These findings complement previously reported data from the TOPAZ trial 24-month extension period that demonstrated sustained and durable improvements in motor function as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE) and RULM in patients with nonambulatory Types 2 and 3 SMA.

No safety risks were identified over 24 months of treatment. The incidence and severity of adverse events were consistent with the underlying patient population and nusinersen therapy. The five most common treatment-emergent adverse events (TEAEs) were headache, pyrexia, upper respiratory tract infection, cough, and nasopharyngitis. No deaths or serious adverse reactions have been observed with apitegromab. A total of 14 serious TEAEs have been reported over the 24-month treatment period, all assessed by the respective trial investigator as unrelated to apitegromab.

Of the 55 patients who completed the 24-month TOPAZ extension period, 54 have opted to continue treatment in the 36-month extension period.

About the Phase 2 TOPAZ Trial

The TOPAZ trial is an ongoing proof-of-concept, open-label Phase 2 trial evaluating the safety and efficacy of apitegromab in patients with Types 2 and 3 SMA. In the main treatment period, patients were dosed intravenously every four weeks as monotherapy or with nusinersen, an approved SMN therapy. The trial enrolled 58 patients in the U.S. and Europe. The primary efficacy endpoints were mean change from baseline in Revised Hammersmith Scale (RHS) score at 12 months for the ambulatory population (Cohort 1), and mean change from baseline in HFMSE score at 12 months for the nonambulatory population (Cohorts 2 and 3). The trial also includes multiple 12-month extension periods designed to evaluate longer-term patient outcomes.

About Apitegromab

Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA). Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. The efficacy and safety of apitegromab have not been established and apitegromab has not been approved for any use by the FDA or any other regulatory agency.

About SMA

Spinal muscular atrophy (SMA) is a rare, and often fatal, genetic disorder that typically manifests in young children. An estimated 30,000 to 35,000 patients are afflicted with SMA in the United States and Europe. It is characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness. The underlying pathology of SMA is caused by insufficient production of the SMN (survival of motor neuron) protein, essential for the survival of motor neurons, and is encoded by two genes, SMN1 and SMN2. While there has been progress in the development of therapeutics that address the underlying SMA genetic defect, via SMN-dependent pathways, there continues to be a high unmet need for therapeutics that directly address muscle function.

About Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, and other product candidates and indication selection and development timing, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as “may,” “might,” “could,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, that preclinical and clinical data, including the results from the Phase 2 clinical trial, including extension periods, of apitegromab are not predictive of, may be inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, including, without limitation, the Phase 3 clinical trial of apitegromab in SMA, Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rock’s ability to obtain, maintain and protect its intellectual property, Scholar Rock’s dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials, Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well as those risks more fully discussed in the section entitled “Risk Factors” in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.

1 Wan HWY, Carey KA, D’Silva A, et al. Orphanet J Rare Dis. 2020;15:70.
2 Yang M. et al. Adv Ther. (2022) 39:1915–1958 https://doi.org/10.1007/s12325-022-02089-2.
3 Cre Care. PEDI-CAT. Accessed April 26, 2022. https://www.pedicat.com/.
4 NIH. PROMIS. Accessed April 26, 2022. https://commonfund.nih.gov/promis/index.
5 Belter L, et al. Orphanet Journal of Rare Diseases. 2020;15:217.
6 Cure SMA. Best Practices for Physical Therapists and Clinical Evaluators in Spinal Muscular Atrophy (SMA). 2021. Available at: https://www.curesma.org/wp-content/uploads/2021/09/Clinical-Evaluators-Best-Practices-13-August-2021.pdf.

Contacts

Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573

Media
Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com
media@scholarrock.com
917-565-2204

The post New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA appeared first on Web Hosting | Cloud Computing | Datacenter | Domain News.

Read more

Filed under Web Hosting News by on #

Different Types Of Dialers – Which One Is Best For You? C-Zentrix Fri, 08/06/2021 – 16:04 Read more about Different Types Of Dialers – Which One Is Best For You? Log in or register to post comments The sales conversation has always bummed people out. A sales call has always been met with some prejudice. To top it off, 44% sales reps actually give up after just 1 follow-up. Does this mean the death of cold calling? No. In fact, cold calling is five to ten times more effective than email campaigns. That being said, to achieve the ideal results your sales reps must keep dialing. However, sloppy dialers and the manual effort always wears out your agents, which in return impacts your cold call success rate. The post Different Types Of Dialers – Which One Is Best For You? appeared first on Web Hosting | Cloud Computing | Datacenter | Domain News.
Read more

Filed under Web Hosting News by on #

PALO ALTO, CA – Jelastic, Multi-Cloud PaaS provider, announced today a partnership with Reclaim Hosting LLC, a web hosting company focused on academic spaces. The launch of Reclaim Cloud opens a Platform as a Service (PaaS) offering to a vast community of educators, universities and other institutions.

“The availability of advanced technologies for educators and students is key to fast innovation. Jelastic is a perfect platform for creating leading-edge projects, arranging productive teamwork and modernizing solutions for various spheres of our lives. Now in cooperation with Reclaim Hosting, the state-of-the-art PaaS becomes easily available for international education institutions,” said Ruslan Synytsky, Jelastic CEO.


“For more than seven years Reclaim Hosting has wanted to provide its users access to a wide range of technologies beyond the traditional LAMP-based cPanel stack. With the demand of next generation applications that run across a wide-range of technology stacks and customized containers, it has become a crucial move for both our community and the future of our company to expand its offerings with Jelastic PaaS,” said Jim Groom, co-founder of Reclaim Hosting.

Reclaim Cloud accelerates development and simplifies application lifecycle management by automating deployment, scaling, clustering, continuous integration and delivery. The launched PaaS is open for all types of projects supporting both traditional (so called legacy) applications and cloud-native microservices. Team collaboration tools, access control and built-in monitoring within a user-friendly developers panel help to ease the management across different projects.

Reclaim Cloud is a container-based server infrastructure that supports a wide-variety of technologies (PHP, Java, Node.js, Python, Ruby, Go, Docker, and more) that not only provide more options, but also increase security and better performance with the ability to scale resources seamlessly. With datacenters in the US, Canada, and the United Kingdom, Reclaim Cloud positions itself at the forefront of the next generation learning environments.

Give a try to Reclaim Cloud powered by Jelastic PaaS or explore more details in the community.

About Jelastic
Jelastic is a Multi-Cloud Platform-as-a-Service that helps customers to focus on their business growth instead of spending resources and team efforts on IT infrastructure configuration and management. The cloud platform is designed for ISVs, digital agencies, e-commerce service providers needing to speed up and simplify applications deployment, reduce infrastructure cost, improve uptime and enhance security of running services. Jelastic automates creation, scaling, clustering and security updates of traditional and cloud-native applications. This PaaS is available as a public, private and hybrid cloud in more than 70 data centers worldwide. Being a multi-cloud platform, it also offers interoperability across AWS, Azure, GCP and other mega clouds. More info at https://jelastic.com

About Reclaim Hosting
Reclaim Hosting LLC provides educators and institutions with an easy way to offer their students domains and web hosting that they own and control. Founded in 2013, their goal is to make the process of offering a flexible web space and domain name to your students as easy as possible and giving you the support you need to make it all happen. More info at https://reclaimhosting.com/

Read more

Filed under Web Hosting News by on #

ATLANTA, GA – Colo Atl, a subsidiary of American Tower announces today that its new Edge Data Center – Atlanta, located in the Ben Hill, GA area, approximately 10 miles southwest of downtown Atlanta, is now fully available to existing and future Colo Atl tenants as an additional interconnection and colocation facility. This latest endeavor is designed to give customers an alternative location to the centralized metro data centers and is strategically located on the network edge. The purpose-built 360-square-foot, 100 KW facility provides eight (8) customer cabinets, comprised of twenty (20) quarter-cabinet lockers and three (3) full cabinets. The connectivity enabled, multitenant, neutral-host edge data center maximizes flexibility and is directly connected via dark fiber to Colo Atl.

“We are very excited to inform our Colo Atl tenants and community about this brand new edge data center asset, made available to all of our customers and ecosystem partners as an additional option for interconnection and colocation,” comments John Ghirardelli, General Manager for Colo Atl and Director, US Innovation for American Tower. “American Tower’s new edge data center, strategically located in close proximity to our Colo Atl facility, enables us to extend the Colo Atl ecosystem with a reliable solution promoting increased flexibility for existing and future customers.”


American Tower’s new edge data centers are being introduced to the market as demands for high bandwidth, low latency applications like cloud computing, artificial intelligence (AI), 5G, Internet of Things (IoT), Big Data, Machine Learning, cybersecurity and AR/VR continue to increase and drive the future of the digital infrastructure landscape.

“Now is the optimal time to invest and pave the way for enabling the next generation network and computing architectures,” adds Whitney Pesot, Product Manager, U.S. Innovation for American Tower. “American Tower is committed to innovation and supporting the needs of our customers now and in the future.”

American Tower Edge Data Centers offer benefits such as:

  • Turnkey Infrastructure: Critical power (primary and backup) distribution, fire monitoring, security, and cooling in an all-in-one edge solution
  • Strategic Location: Utilizing the ground space of our existing towers, where connectivity already occurs, we create an improved network architecture closer to key operators
  • Reliability: Exceptional performance and reliability with guaranteed network service levels and 24/7/365 network operations center (NOC)
  • Security: Secure location with full DCIM capability and access control including 24/7/365 site monitoring
  • Dependability: Work with a single, trusted and established company for both tower and edge data colocation to simplify network deployment

For a tour or to discuss the Colo Atl facility and/or edge data center location, visit https://coloatl.com/atc/ or contact Sam Reagin, Business Development Leader for Colo Atl at sam.reagin@coloatl.com or (678) 521-3898.

About Colo Atl
Colo Atl, an American Tower company, is the leading provider of carrier-neutral colocation, data center and interconnection solutions at 55 Marietta Street in the global telecom hub of Atlanta, GA. Colo Atl provides superior carrier-neutral colocation, data center and interconnection services at an affordable rate. Colo Atl is a carrier-neutral environment that allows all types of network operators to securely and conveniently cross connect within a SOC 1 Type II certified facility. Colo Atl has no monthly recurring cross connect fees between tenants within the Colo Atl Meet-Me-Area (MMA) and provides exceptional customer service. Colo Atl is also home to the Georgia Technology Center (GTC), a live laboratory for network equipment vendors to highlight their optical and electrical hardware and operating systems, and the Southeast Network Access Point (SNAP), which provides next-generation Internet Exchange (IX) solutions, including SDN peering, testing, collaboration and implementation.

About American Tower
American Tower is a leading independent owner, operator and developer of wireless and broadcast communication real estate. Our global portfolio includes approximately 180,000 communications sites and is experiencing steady growth. In addition to leasing space on towers, we provide customized collocation solutions through our in-building systems, outdoor distributed antenna systems and other right-of-way options, managed rooftops and services that speed network deployment.

Read more

Filed under Web Hosting News by on #

Amsterdam, the Netherlands – 3W Infra, a global IaaS hosting provider from the Netherlands, has moved its headquarters to the office space in the maincubes AMS01 colocation data center in Amsterdam Schiphol-Rijk while deploying a private suite in this data center for its global network backbone and comprehensive server infrastructure. According to 3W Infra’s founder and CEO, Murat Bayhan, 3W Infra selected the maincubes AMS01 facility “as maincubes is the only true independent and European data center operator left in the Amsterdam area able to meet 3W Infra’s flexibility and scalability requirements.”

3W Infra had its HQs as well as its server and network infrastructure located in another facility in Amsterdam. During their tenancy this facility was acquired and became part of a global data center conglomerate. 3W Infra delivers highly customer-specific IaaS hosting infrastructures, closely tailored to individual needs, meaning they expect the highest flexibility approach from their data center operator as well. According to 3W Infra, the existing facility isn’t able to fully respond to these dynamic demands.


As a privately-owned European data center operator with energy-efficient and sustainably operated colocation facilities located in Frankfurt, Germany, and Amsterdam, the Netherlands, maincubes provides colocation services from its AMS01 facility for small up to large (multiple MW) deployments, and from rack by rack and cages up to private suites as well as data center in data center setups. maincubes is able to provide 3W Infra with the flexibility and scalability options the company is looking for. The private data center suite offered to 3W Infra has been commissioned at the end of May. At the same time, 3W Infra has moved its headquarters to maincubes AMS01.

Network Backbone Upgrade

3W Infra owns/operates a high-volume global backbone with redundant design. The company’s dedicated dark fiber ring in the Amsterdam region is at the basis of this network, connecting 5 data center Points-of-Presence (PoPs) in Amsterdam. As a hyper connected data center, the maincubes AMS01 facility will now be used as the main network PoP for 3W Infra’s global backbone and be home to its newly purchased network equipment, distributing 3W Infra’s new multiple 100G Transit ports across all PoPs in the Amsterdam area. The migration of this network equipment will take place during the coming weeks.

“maincubes AMS01 in Amsterdam Schiphol-Rijk will now become our flagship data center, providing us with the highest colocation service flexibility we could wish for,” said Murat Bayhan, founder and CEO of 3W Infra. “The fact that maincubes is privately owned and probably the only true independent and European data center operator left in the Amsterdam area works to their advantage. That’s my opinion. They are willing to adapt to the dynamic and unpredictable client needs to which we must respond as an IaaS hosting company. They are perfectly able to meet 3W Infra’s flexibility and scalability requirements, also quickly, allowing us to rapidly deploy highly customized IaaS hosting setups. maincubes acts as a strategic business partner for us, so to say.”

New HQs, OCP, Immersion Cooling

The maincubes AMS01 data center is also home to the European Open Compute Project (OCP) Experience Center, operated by data center vendor Rittal and official OCP solutions provider Circle B. It is available as a demo center, while it can also be used to test new ‘OCP Accepted’ and ‘OCP Inspired’ data center environments as well as telecom solutions. Next to that, maincubes is offering ‘immersion cooling’ (liquid cooling) solutions in dedicated immersion cooling colocation suites in its Amsterdam AMS01 data center, aiming for HPC, AI and machine learning workload deployments.

“As an IaaS hosting provider, we definitely like these extras,” added Mr. Bayhan. “It’s not just colocation maincubes is providing us and it’s quite an innovative and absolutely unique approach, I have to say. I’ve never seen a colocation provider offering so many extra’s under one roof, with different sustainable and state-of-the-art technology solutions to select and use.”

“We’re providing Murat and his team with the ability to scale their infrastructure whenever needed,” said Joris te Lintelo, Vice President Sales at maincubes. “We’re also empowering them with a highly flexible approach. And if they would like to, they can test these new and innovative technologies or offer them to their clients. We’ll make sure they will feel right at home here. On top of that, the office and storage space we offer 3W Infra at maincubes AMS01 allow their engineers to quickly respond to provisioning requests or any requests that may occur.”

About maincubes
maincubes is part of German investor and real estate developer Art-Invest which is part of the German construction conglomerate Zech Group. maincubes has data centers in Frankfurt and Amsterdam, and a network of high-availability data centers of various sizes and types in Europe, enabling it to provide colocation services and secure ecosystems for the digital future of customers across various industries. Via the secureexchange® digital platform customers and partners of maincubes can use IT services worldwide such as IoT, (cyber) security and connectivity as well as cloud services to expand their business opportunities. maincubes offers secure, efficient and user-friendly services – and a secure home for your data. To learn more about maincubes, visit https://www.maincubes.com/

About 3W Infra
Founded in 2014 by some Internet and hosting industry veterans, 3W Infra is a global Infrastructure-as-a-Service (IaaS) hosting provider with great engineering knowledge and skills headquartered in Amsterdam, the Netherlands. Its global network backbone now exceeds 320 Gigabit/sec (Gbps) of available bandwidth. The company’s enterprise-grade, ISO 27001 and PCI DSS certified hosting solutions are tailored to the specific needs of each customer. 3W Infra’s infrastructural solutions are engineered for scalability and costefficiency, with cloud-enabling services including colocation, dedicated servers, IP connectivity, and high-level customer support. These solutions come with 3W Infra’s Remote Hands including relocation engineering services at the world’s main Internet hubs in Amsterdam, Frankfurt and London. 3W Infra’s customer base includes some of the largest Internet, gaming, broadcasting and cloud services companies in Europe and beyond. To learn more about 3W Infra, visit https://www.3winfra.com/

Read more

Filed under Web Hosting News by on #

Los Angeles, CA — RackNerd LLC, a dedicated server, complex hosting, cloud, disaster recovery, colocation, and infrastructure services provider today announced the launch of its new product offering: DDoS Protected Virtual Private Servers (VPS). DDoS Protected VPS services, powered by KVM virtualization, will be deployed out of its new Los Angeles DC-05 facility, featuring 60Gbps of DDoS protection included with every plan.

Its on-the-fly engine fine-tunes distributed denial-of-service attacks in real-time to mitigate even the most sophisticated examples — mitigating attack traffic that would otherwise result in downtime.


With security and uptime emphasized, this sophisticated protection service proactively detects and filters complex network security threats. The result: a seamless experience where end-users encounter no downtime or increased latency.

“In recent studies, it has been found that a single DDoS attack costs some businesses as much as $2.5 million in lost revenue. With network related attacks evolving to become a serious concern for businesses around the globe, very few fine-tuned, proactive mitigation solutions existed in the marketplace until now.” discloses Dustin B. Cisneros, CEO of RackNerd LLC.

The destructive impact of DDoS attacks can result in website downtime, degraded server performance, website vulnerability, and most importantly: lost time, productivity, and revenue. An analysis by Kaspersky Lab Research announced that DDoS attacks are continuing to rise globally, costing both financial and reputational damage for many organizations.

“In these times where online presence is more critical than ever before, it is essential for businesses to have a plan in place to mitigate today’s sophisticated network attacks. Our enterprise-grade DDoS mitigation service is designed with the future in mind. DDoS attacks of all shapes, sizes, and types are stopped automatically without any manual intervention from our customers. New attack patterns are learned and systematically filtered.” Cisneros added.

Businesses looking to deploy upon DDoS protected infrastructure can now benefit from RackNerd’s new product offering. To learn more, please visit: https://www.racknerd.com/ddos-protected-vps

About RackNerd
RackNerd LLC introduces infrastructure stability and provides Dedicated Servers, Private Cloud solutions, DRaaS (Disaster-Recovery-as-a-Service), flexible Colocation, Virtual Private Servers and advanced DDoS Mitigation services — maintained by a team with decades of experience in managed services, datacenter operations, and Infrastructure-as-a-Service. With an intrinsic focus on client success and growth, RackNerd has grown steadily while continuing to provide high-quality hosting services at competitive rates.

Read more

Filed under Web Hosting News by on #